IL-6 receptor blockade with TCZ has been demonstrated to induce a positive balance of bone markers by increasing the P1NP level and reducing the CTX level in patients with established RA who had inadequate responses to MTX or TNF inhibitors [13, 26]. Here, TNF is linked to rheumatoid arthritis.